We will be reviewing the following landmark papers regarding the Ocular Hypertension Treatment Study

Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA,
Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular
Hypertension Treatment Study: baseline factors that predict the onset of primary 
open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. 
PubMed PMID: 12049575.

Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, 
Miller JP, Parrish RK, Wilson MR; Ocular Hypertension Treatment Study Group.
Delaying treatment of ocular hypertension: the ocular hypertension treatment
study. Arch Ophthalmol. 2010 Mar;128(3):276-87. PubMed PMID: 20212196.

Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and
baseline description of the participants. Arch Ophthalmol. 1999
May;117(5):573-83. PubMed PMID: 10326953.

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish
RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a
randomized trial determines that topical ocular hypotensive medication delays or 
prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002
Jun;120(6):701-13; discussion 829-30. PubMed PMID: 12049574.